Eucrisa...everthing depends on PRICE

Discussion in 'Pfizer' started by anonymous, Nov 16, 2016 at 11:01 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Sure, we don't have the label yet, but the draft label looks good.

    Sure, we don't have the efficacy, but safety sells in dermatology.

    EVERYTHING comes down to price. If we price this thing at $100-$150 a month, then we can get everything.

    If we pull a Xeljanz and think route of delivery is worth a premium, we are screwed.

    Please HQ, please let us win.
     

  2. anonymous

    anonymous Guest

    Then we are screwed. We will charge a premium just to make up for our other blunders.

    Regeneron is launching end of March. We have 3 months to frame everything. Can't do it if our cream costs $1000 a month. PBMs aren't going to allow that.
     
  3. anonymous

    anonymous Guest

    The Regeneron product and ours will be for different populations. Ours should be more like 100/month. Regeneron will charge a premium--look at how their cholesterol drug is priced.
     
  4. anonymous

    anonymous Guest

    You all sound ill informed. The majority of dermatology products are super expensive. Derms won't bat an eye at a hefty price tag. They see them all the time. The key to this drug is gaining managed care access and developing a low cost way to obtain it like 90% of the derm products out there. As long as the data is good, this product should do pretty well.
     
  5. anonymous

    anonymous Guest


    you sound a bit simple minded. look, managed care access is important but the data is already in and the products are entirely different. dupilumab inhibits iL-4 and iL-13 and has far superior efficacy than crisaborole which attempts to maintain the integrity of skin after irritation has begun. dupilumab will be even better in patients who have eosinophilia.

    if Pfizer is smart, they will sell safety, safety and then safety with a little bit of convenience to keep it fresh. why even mention efficacy. this product will be indicated for infants as well as adults. they will get all the mild business. dupilumab will get all the severe. the fight is over the middle - the moderate patients.

    to get the moderate patients, you don't need managed care access because both dupilumab and crisoborole will likely be sitting behind managed care access criteria -what you need is an effective sales force. not an effective TV campaign, not an effective marketing team, not a clever trade strategy but an effective sales team.

    good luck
     
  6. anonymous

    anonymous Guest

    Sometimes simplicity is best. Too often we try to over complicate things instead of just going out and being a great sales rep.